logo
Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed

Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed

Medscape11-07-2025
TOPLINE:
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions.
METHODOLOGY:
Researchers conducted a systematic review of 62 studies describing 63 patients (average age, 29.9 years) with PG during pregnancy or up to 6 weeks postpartum through September 2023.
Of all patients, 27% of patients had a history of PG or PG-like symptoms, 7.9% had a history of inflammatory bowel disease, and 4.8% had another systemic rheumatologic disease. In 71.4% of cases, preceding trauma to the skin was reported.
Outcomes included the misdiagnosis rate, treatment, and maternal and fetal complications.
TAKEAWAY:
During pregnancy, 15.9%, 11.1%, and 7.9% of cases appeared in the first, second, and third trimesters, respectively, while 65.1% were postpartum — primarily at the site of cesarean section scars (55.6%).
Of the 47 cases where an initial diagnosis was reported, only 2 cases were recognized as PG; 45 (95.7%) were initially misdiagnosed as bacterial infections, necrotizing fasciitis, or another skin disorder. Among the 26 cases with data on time to diagnosis, the diagnosis was delayed by more than 7 days in 77%.
Before the diagnosis of PG, surgical wound intervention and broad-spectrum antibiotics were the most frequent treatments, whereas systemic corticosteroids (88.9%) and cyclosporine (33.3%) were most commonly used after PG was diagnosed. All patients showed improvement after treatment, and treatment-related adverse effects were uncommon.
Cesarean section was performed in 40 cases, and 22 of 41 cases with gestational age data were preterm, and there was one case of intrauterine fetal demise.
IN PRACTICE:
These results highlighted 'the frequent misdiagnosis of PG in this population, leading to treatment delays and inappropriate interventions that worsen the condition,' the authors of the study wrote. The study, 'supported by immunological research,' suggested that pregnancy 'may independently contribute to the development of PG,' they added, noting that further research on safe and effective treatment protocols is needed.
SOURCE:
This study was led by Gretchen D. Ball, and Sarah Romanelli, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, and was published online on June 30 in the Journal of Drugs in Dermatology.
LIMITATIONS:
This study was limited by its small sample size and inconsistencies in data reporting across case reports. Collecting comprehensive pregnancy outcomes data was challenging due to limited pregnancy details provided in dermatology journals.
DISCLOSURES:
This study was supported by the International Dermatology Outcome Measures nonprofit group. One author disclosed receiving grants and honoraria, and holding stocks in various organizations, including Amgen, AnaptysBio, Avotres Therapeutics, Eli Lilly and Company, Novartis, Sanofi, and XBiotech.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Obesity to fuel rise in liver cancer cases
Obesity to fuel rise in liver cancer cases

Yahoo

time3 hours ago

  • Yahoo

Obesity to fuel rise in liver cancer cases

The number of cases of liver cancer are set to double by 2050, with rising cases of obesity partly to blame, academics have said. The proportion of cases of liver cancer linked to obesity are set to increase from 5% to 11%, a group of experts has said as they called for more to be done to tackle preventable cases from occurring in the first place. The number of new liver cancers around the world will rise from 0.87 million in 2022 to 1.52 million in 2050, according to projections published as part of a new Lancet Commission on Liver Cancer paper. Researchers said that the proportion of liver cancers caused by the most common cause of liver cancer – the hepatitis B virus – are set to reduce over the coming years. Cases caused by the hepatitis C virus are also expected to decline proportionately. But in contrast, liver cancer cases caused by alcohol and obesity are set to increase. Experts predicted that by 2050 some 21% of liver cancers will be caused by alcohol. And 11% will be caused by a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) – formerly known as fatty liver disease, where fat builds up in a person's liver. The severe form of this condition is called metabolic dysfunction-associated steatohepatitis. The research team point out that 60% of liver cancers are preventable. They said that global deaths from liver cancer are expected to rise from 760,000 in 2022 to 1.37 million in 2050. 'These data suggest that preventive measures targeting a comprehensive number of risk factors for hepatocellular carcinoma are sorely needed,' the team of experts led by academics in Hong Kong wrote. The main treatment for MASLD is eating a balanced diet, being physically active and potentially losing weight. 'Liver cancer is a growing health issue around the world,' said Professor Jian Zhou, chairman of the Commission from Fudan University in China. 'It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5% to 30%. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend.' First author, Professor Stephen Chan, from the Chinese University of Hong Kong, added: 'As three in five cases of liver cancer are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity, there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives.' Commenting on the study, Pamela Healy, chief executive of the British Liver Trust, said: 'Liver cancer is the fastest rising cause of cancer death in the UK, and just 13% of people diagnosed will survive for five years or more. 'We know that the biggest risk factors are having pre-existing liver cirrhosis or viral hepatitis, and this new analysis highlights that MASLD, also known as fatty liver disease, is expected to be linked to an increasing number of cases. 'As well as improving early detection through surveillance of people with cirrhosis, it is essential that we tackle these underlying causes and prioritise public health. 'By supporting people to maintain a healthy weight, cut down on alcohol and get tested and treated for hepatitis, we can prevent many cases of liver cancer and save lives.' In 2022, some 64% of adults in England were estimated to be overweight or living with obesity.

Rising obesity rates will see cases of liver cancer double by 2050, study warns
Rising obesity rates will see cases of liver cancer double by 2050, study warns

Yahoo

time3 hours ago

  • Yahoo

Rising obesity rates will see cases of liver cancer double by 2050, study warns

The number of cases of liver cancer are set to double by 2050, academics have said. The rising cases of obesity are partly to blame. The proportion of cases of liver cancer linked to obesity are set to increase from 5 per cent to 11 per cent, a group of experts has said. They also called for more to be done to tackle preventable cases from occurring in the first place. The number of new liver cancers around the world will rise from 0.87 million in 2022 to 1.52 million in 2050, according to projections published as part of a new Lancet Commission on Liver Cancer paper. Researchers said that the proportion of liver cancers caused by the most common cause of liver cancer – the hepatitis B virus – are set to reduce over the coming years. Cases caused by the hepatitis C virus are also expected to decline proportionately. But in contrast, liver cancer cases caused by alcohol and obesity are set to increase. Experts predicted that by 2050 some 21 per cent of liver cancers will be caused by alcohol. And 11 per cent will be caused by a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) – formerly known as fatty liver disease, where fat builds up in a person's liver. The severe form of this condition is called metabolic dysfunction-associated steatohepatitis. The research team point out that 60 per cent of liver cancers are preventable. They said that global deaths from liver cancer are expected to rise from 760,000 in 2022 to 1.37 million in 2050. 'These data suggest that preventive measures targeting a comprehensive number of risk factors for hepatocellular carcinoma are sorely needed,' the team of experts led by academics in Hong Kong wrote. The main treatment for MASLD is eating a balanced diet, being physically active and potentially losing weight. 'Liver cancer is a growing health issue around the world,' said Professor Jian Zhou, chairman of the Commission from Fudan University in China. 'It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5 per cent to 30 per cent. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend.' First author, Professor Stephen Chan, from the Chinese University of Hong Kong, added: 'As three in five cases of liver cancer are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity, there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives.' Commenting on the study, Pamela Healy, chief executive of the British Liver Trust, said: 'Liver cancer is the fastest rising cause of cancer death in the UK, and just 13 per cent of people diagnosed will survive for five years or more. 'We know that the biggest risk factors are having pre-existing liver cirrhosis or viral hepatitis, and this new analysis highlights that MASLD, also known as fatty liver disease, is expected to be linked to an increasing number of cases. 'As well as improving early detection through surveillance of people with cirrhosis, it is essential that we tackle these underlying causes and prioritise public health. 'By supporting people to maintain a healthy weight, cut down on alcohol and get tested and treated for hepatitis, we can prevent many cases of liver cancer and save lives.' In 2022, some 64 per cent of adults in England were estimated to be overweight or living with obesity.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store